Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Int J Neuropsychopharmacol ; 25(11): 933-935, 2022 Nov 17.
Article in English | MEDLINE | ID: covidwho-1973164


Chemosensory (i.e., olfaction and taste) dysfunction is common in neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease, and dementia), psychiatric (e.g., depression, bipolar disorders, other conditions), and postinfectious (i.e., long COVID) diseases and in the elderly. Despite its impact on patients' quality of life, no established treatment for taste disorders exists so far. A recent report on the effect of pramipexole, a D2/D3 agonist, on taste performance in healthy participants provides support for a new potential therapeutic target for taste dysfunction to be tested in future randomized, placebo-controlled, clinical trials across several populations reporting gustatory symptoms.

COVID-19 , Parkinson Disease , Humans , Aged , Pramipexole , Dopamine Agonists/therapeutic use , Receptors, Dopamine D3 , Parkinson Disease/complications , Parkinson Disease/drug therapy , Parkinson Disease/physiopathology , Dopamine , Healthy Volunteers , Taste , Quality of Life , Benzothiazoles , Taste Disorders/drug therapy , Taste Disorders/etiology
Nutr Rev ; 80(5): 1086-1093, 2022 04 08.
Article in English | MEDLINE | ID: covidwho-1337279


Zinc supplementation is indicated for diarrhea and taste disorders, which are both features of COVID-19 . Nevertheless, this strategy has not been tested for the treatment of these secondary complications in the current pandemic. Through an updated review, a practical appraisal was considered as a means of providing a medical nexus of therapeutic zinc regimens as an adjunct in the management of COVID-19-related diarrhea and ageusia/dysgeusia. While diarrhea and taste disorders are consequences of COVID-19, zinc supplementation is useful for non-COVID-19 patients with these clinical problems. The overwhelming evidence for supplementing with zinc in diarrhea and pneumonia is associated with the treatment of children, while for taste disorders the use of supplementing with zinc is more examined in adults. Whereas COVID-19 is more prevalent in adults, precautions should be exercised not to translate the zinc dosage used for children with diarrhea and taste disorders into the current pandemic. Therapeutic doses of zinc used for adults (∼50-150 mg/day of elemental zinc) could be included in the treatment strategies for COVID-19, but this proposal should be examined through randomized studies.

Ageusia , Adult , Ageusia/complications , Ageusia/drug therapy , Child , Diarrhea/drug therapy , Dietary Supplements , Dysgeusia/drug therapy , Dysgeusia/etiology , Humans , Taste Disorders/complications , Taste Disorders/drug therapy , Zinc/therapeutic use
Pharmacol Rep ; 73(3): 781-785, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1099023


BACKGROUND: The benefits of corticosteroids for the treatment of COVID-19 infection are documented in the literature. The goal of the study is to compare the severity of rhinological symptoms of COVID-19 between patients with nasal steroid use (NSU) and the control group (CG) using the sino-nasal outcome test (SNOT-22) questionnaire. METHODS: A face-to-face survey was conducted at a second referral state hospital between. Patients with a complete recovery from COVID-19 were included in NSU and CG groups. Two subscales of the SNOT-22 were filled by the patients. The frequency and duration of smell and taste loss and SNOT-22 scores were compared between the two groups. RESULTS: Forty-seven patients were included in the study. Thirty-one patients were in CG and 16 patients in the NSU group. Twenty-four (51.1%) patients were females and 23 (48.9%) were males. The mean age was 41.4 ± 8.6 years. Olfactory dysfunction was detected in 12 (75%) patients in the NSU group, and 31 (93.3%) patients in the control group (CG). Gustatory dysfunction was seen in 10 (62.5%) patients in the NSU group and 24 (77.4%) patients NSU group. (p = 0.071, 0.279, respectively). The duration of the olfactory (6.6 ± 2.5 days) and gustatory dysfunction (6.1 ± 2.6 days) and the mean SNOT-22 total score (11.9 ± 1.6) was significantly lower in the NSU group (p < 0.001, CI 11.1-5.1, CI 9.9-4.6, CI 9.3-5.9, respectively). CONCLUSIONS: Although nasal steroid use does not prevent olfactory and gustatory dysfunction in COVID-19 patients, it may reduce the severity and duration of these symptoms.

Olfaction Disorders/drug therapy , Steroids/therapeutic use , Taste Disorders/drug therapy , Adult , Female , Humans , Male , Olfaction Disorders/virology , SARS-CoV-2 , Sino-Nasal Outcome Test , Smell/drug effects , Surveys and Questionnaires